- Home
- GRAL vs ABVX Comparison
GRAL vs ABVX Comparison
Compare GRAL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- ABVX
- Stock Information
- Founded
- GRAL 2016
- ABVX 2013
- Country
- GRAL United States
- ABVX France
- Employees
- GRAL N/A
- ABVX N/A
- Industry
- GRAL
- ABVX
- Sector
- GRAL
- ABVX
- Exchange
- GRAL NYSE
- ABVX Nasdaq
- Market Cap
- GRAL 610.9M
- ABVX 722.3M
- IPO Year
- GRAL N/A
- ABVX N/A
- Fundamental
- Price
- GRAL $18.35
- ABVX $7.65
- Analyst Decision
- GRAL Hold
- ABVX Strong Buy
- Analyst Count
- GRAL 2
- ABVX 6
- Target Price
- GRAL $16.00
- ABVX $38.67
- AVG Volume (30 Days)
- GRAL 1.2M
- ABVX 132.7K
- Earning Date
- GRAL 02-15-2025
- ABVX 09-09-2024
- Dividend Yield
- GRAL N/A
- ABVX N/A
- EPS Growth
- GRAL N/A
- ABVX N/A
- EPS
- GRAL N/A
- ABVX N/A
- Revenue
- GRAL $117,669,000.00
- ABVX $9,676,417.00
- Revenue This Year
- GRAL $32.48
- ABVX $31.67
- Revenue Next Year
- GRAL $14.72
- ABVX $1,189.66
- P/E Ratio
- GRAL N/A
- ABVX N/A
- Revenue Growth
- GRAL 111.83
- ABVX 100.87
- 52 Week Low
- GRAL $12.33
- ABVX $7.11
- 52 Week High
- GRAL $24.92
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- ABVX 37.23
- Support Level
- GRAL N/A
- ABVX $7.49
- Resistance Level
- GRAL N/A
- ABVX $8.18
- Average True Range (ATR)
- GRAL 0.00
- ABVX 0.46
- MACD
- GRAL 0.00
- ABVX 0.00
- Stochastic Oscillator
- GRAL 0.00
- ABVX 28.27
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.